Needham & Company Reiterates a 'Hold' on ISIS Pharmaceuticals (ISIS); FDA Views Mipomersen Data as Sufficient to Submit HoFH NDA
Tweet Send to a Friend
Needham & Company reiterates a 'Hold' on ISIS Pharmaceuticals (NASDAQ: ISIS).
Needham analyst says, "Yesterday, ISIS updated the regulatory strategy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Yesterday, ISIS updated the regulatory strategy ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
